New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2013
11:34 EDTMJN, IRBT, NEPT, LSI, DNBHigh option volume stocks: DNB NEPT MJN LSI IRBT
News For DNB;NEPT;MJN;LSI;IRBT From The Last 14 Days
Check below for free stories on DNB;NEPT;MJN;LSI;IRBT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
12:59 EDTNEPTNeptune shares higher by over 3% after U.S grants patent related to Alzheimer's
Earlier today, Neptune Technologies & Bioressources announced that the U.S. Patent & Trademark Office, USPTO, has granted Neptune a new continuation patent relating to the treatment of Alzheimer's.The patent, which is the corporation's first specifically targeting neurological conditions, is granted for the US market and is valid until 2022. The claims focus on treating Alzheimer's disease by administering an effective amount of a phospholipid composition, wherein the phospholipid composition comprises DHA and EPA. "Today's announcement provides additional strength to our patent estate and highlights our commitment to continue to protect and build this valuable asset for both our nutraceutical and pharmaceutical businesses," highlighted Mr. Henri Harland, President and CEO of Neptune. "Neurological disorders, such as Alzheimer's, are growing and new methods to prevent and treat such conditions using alternative treatments are continuously being sought out. In addition to Neptune, this new patent substantially benefits our subsidiary, NeuroBioPharm, as it continues to develop omega-3 phospholipid products for neurological pharmaceutical applications."
10:56 EDTIRBTOptions with decreasing implied volatility: IRBT FB FTNT ILMN CMG
Subscribe for More Information
07:04 EDTMJNMead Johnson raises FY14 EPS view to $3.60-$3.72 from $3.50-$3.62
Consensus $3.62. In the first quarter of 2014, MJN adopted mark-to-market accounting for all of its defined benefit pension and other post-employment benefit plans. Of the expected 10c increase in earnings per share, approximately two-thirds is attributed to the New Pension Accounting with the remainder the result of stronger anticipated operational performance. To provide a better view of underlying operational performance, pension MTM actuarial gains or losses will be treated as a Specified Item. The company now anticipates constant dollar sales growth of approximately 8% for the full year 2014, up from 7% in its prior guidance, consensus $4.44B.
07:02 EDTMJNMead Johnson reports Q1 EPS $1.02, consensus 91c
Subscribe for More Information
April 23, 2014
16:09 EDTLSILSI Corp. reports Q1 EPS 17c, consensus 15c
Subscribe for More Information
11:43 EDTIRBTiRobot reiterated as a Buy on weakness at Needham
Subscribe for More Information
10:40 EDTIRBTOptions with decreasing implied volatility: SRPT CREE NFLX IRBT SVU
Subscribe for More Information
09:44 EDTIRBTiRobot falls after earnings and view, levels to watch
Subscribe for More Information
April 22, 2014
16:14 EDTIRBTiRobot sees FY14 EPS $1.00-$1.15, consensus $1.11
Subscribe for More Information
16:13 EDTIRBTiRobot sees Q2 EPS 15c-25c, consensus 23c
Sees Q2 revenue $138M-$145M, consensus $143.8M.
16:12 EDTIRBTiRobot reports Q1 EPS 18c, consensus 16c
Reports Q1 revenue $114.2M, consensus $112.26M.
April 21, 2014
14:05 EDTNEPTNeptune says '348 patent still valid, to appeal USPTO decision
Neptune Technologies & Bioressources (NEPT) announced that the United States Patent and Trademark Office, or USPTO, recently issued a Right of Appeal Notice in an inter partes reexamination of Neptune's '348 patent. Despite the USPTO's decision, the '348 patent is still valid as Neptune has the right to appeal, which it intends to do, the company said. "Enzymotec (ENZY), in yet another clear attempt to shift focus from the on-going International Trade Commission investigation of its infringement of other Neptune patents, issued a press release addressing the '348 Patent decision. However, Enzymotec failed to highlight that the decision has no impact on the ITC investigation into infringement of Neptune's other composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. Furthermore, the decision has no impact on Neptune's license agreements with Rimfrost and Aker BioMarine," said Neptune.
08:09 EDTNEPTEnzymotec says USPTO issues final decision, rejects all claims in Neptune patent
Subscribe for More Information
April 17, 2014
07:33 EDTDNBD&B acquires Fliptop's social data matching business unit
Subscribe for More Information
April 16, 2014
13:54 EDTMJNDanone slips after fresh dairy volume shrinks
Subscribe for More Information
April 14, 2014
14:23 EDTIRBTiRobot May volatility elevated at 61
Subscribe for More Information
10:23 EDTLSIHigh option volume stocks: CCL WCG LSI INTU IACI
Subscribe for More Information
April 11, 2014
09:44 EDTIRBTiRobot revokes poison pill in 8K, says Raymond James
Raymond James said iRobot's board revoked their poison pill, which could fuel takeover speculation.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use